You are here: Industry Insights > Mallinckrodt

News List

Federal judge scolds Purdue, Endo and Mallinckrodt for stall tactics in opioids case fiercepharma
April 23, 2019
U.S. District Judge Dan Polster has had enough of opioids makers Purdue Pharma, Endo and Mallinckrodt asking for extensions in the multistate lawsuit against them.
Mallinckrodt's INOmax (Nitric Oxide) Gas, for Inhalation, Approved in Australia for Pulmonary Hypertension in Adults in Conjunction with Cardiovascular Surgery firstwordpharma
April 11, 2019
Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company……
Mallinckrodt's INOmax receives approval in Australia biospectrumasia
April 11, 2019
INOmax was previously approved for this same indication in neonates through adolescents up to age 17……
Piramal Critical Care Announces the U.S. Launch of MITIGO™ americanpharmaceuticalreview
March 12, 2019
Piramal Critical Care announced the launch of MITIGO™ (Morphine Sulfate Injection, USP – Preservative-free) in 10 mg/mL and 25 mg/mL concentrations in the U.S. market.
Mallinckrodt invests $100M in its BioVectra CDMO en-cphi.cn
March 08, 2019
The Canadian operations plant where Mallinckrodt makes the API for its controversial—and pricey—H.P. Acthar Gel is expanding and getting some Canadian tax dollars to help with the expense.
Mallinckrodt announces collaboration agreement of extracorporeal photoapheresis (FEC) with Transimmune AG pharmafocusasia
February 27, 2019
Mallinckrodt plc, the world's leading pharmaceutical specialty company, today announced that it has signed a research collaboration agreement with Transimmune AG....
Mallinckrodt Announces Interim Analysis Results for Therakos Platform Trial americanpharmaceuticalreview
February 22, 2019
Mallinckrodt announced interim analysis results of its company-sponsored, Phase 3, single-arm, open-label, multi-center study assessing the efficacy of treating steroid-refractory ....
Mallinckrodt spinoff to include 7 manufacturing sites in U.S. and Japan fiercepharma
December 19, 2018
With its plan for a spinoff into two companies, Mallinckrodt will create an API and generics operation with a large controlled substances and acetaminophen business and seven manufacturing facilities split between the U.S. and Japan.
FDA rejects Mallinckrodt's abuse-deterrent version of opioid painkiller Roxicodone pharmafile
December 13, 2018
Mallinckrodt has hit a snag in its quest to bring an abuse-deterrent version of Roxicodone (oxycodone hydrochloride) to market in the US, as it emerges that the FDA saw fit to reject the opioid...
FDA rejects Mallinckrodt’s abuse-deterrent form of Roxicodone pharmatimes
December 13, 2018
Mallinckrodt's SpecGx division has announced the rejection of its abuse-deterrent re-formulation of opioid analgesic Roxicodone by the US Food and Drug Administration (FDA).

Previous page 1 2 3 4 5 Next page